Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 8 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Universität Zürich has 13 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 13 actions are spread across 13 distinct examiners, ensuring that no individual examiner is responsible for more than one matter. DEUTSCH, TAYLOR M is the busiest examiner for the portfolio, holding 1 pending office action.
The portfolio's activity is distributed across 10 distinct art units, which highlights the broad technical range of the university's biotechnology research. With 13 distinct examiners and 10 distinct art units, the 13 pending office actions are subject to a high degree of variation in examination standards and individual examiner perspectives.
This decentralized structure means that practitioners must tailor their strategies for each of the 13 pending office actions. The presence of 10 distinct art units for only 13 pending office actions suggests that the university's innovations are highly specialized and diverse, requiring engagement with many different divisions at the USPTO.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (27%) |
| §103 only | 2 (18%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEUTSCH, TAYLOR M | 1 | 53.4% | +37.2% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| NGUYEN, SANG H | 1 | 88.7% | +11.7% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
| CRUM, MARY ABOU NADER | 1 | 40.4% | +65.0% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| HADDAD, MAJD MAHER | 1 | 100.0% | +0.0% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 19d overdue |
| 18873352 | IONOPHORIC COPPER-CHELATORS IN COMBINATION WITH MAPK INHIBITORS FOR USE IN TREATMENT OF CANCER | CHONG, YONG SOO | — |
| 18865873 | OPTICAL SENSOR AND ASSOCIATED METHODS | NGUYEN, SANG H | — |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | IVICH, FERNANDO NMN | — |
| 18580742 | Treatment and/or Prevention of Digestive Disorder by a Bacterial Composition of Propionibacterium Freudenreichii and Bifidobacterium Longum | CRUM, MARY ABOU NADER | — |
| 18497735 | ANTI-BK VIRUS ANTIBODY MOLECULES | SZPERKA, MICHAEL EDWARD | — |
| 18491017 | NEURAL NETWORK CIRCUIT WITH DELAY LINE | HADDAD, MAJD MAHER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019382 | ANTIMICROBIAL PEPTIDOMIMETICS | KONOPELSKI SNAVEL, SARA ELIZABETH | 8d overdue |
| 18019388 | ANTIMICROBIAL PEPTIDOMIMETICS | BEANE, RANDALL L | 14d |
| 19138132 | SCAR LIGHT MANIPULATOR | DEUTSCH, TAYLOR M | — |
| 18873352 | IONOPHORIC COPPER-CHELATORS IN COMBINATION WITH MAPK INHIBITORS FOR USE IN TREATMENT OF CANCER | CHONG, YONG SOO | — |
| 18865873 | OPTICAL SENSOR AND ASSOCIATED METHODS | NGUYEN, SANG H | — |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | IVICH, FERNANDO NMN | — |
| 18580742 | Treatment and/or Prevention of Digestive Disorder by a Bacterial Composition of Propionibacterium Freudenreichii and Bifidobacterium Longum | CRUM, MARY ABOU NADER | — |
| 18497735 | ANTI-BK VIRUS ANTIBODY MOLECULES | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 3798 | 1 |
| 2877 | 1 |
| 1657 | 1 |
| 1641 | 1 |
| 4100 | 1 |
| 1654 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19138132 | SCAR LIGHT MANIPULATOR | DEUTSCH, TAYLOR M | 3798 | §103 | Non-Final OA | — | Pending | Jun 12, 2025 |
| 18873352 | IONOPHORIC COPPER-CHELATORS IN COMBINATION WITH MAPK INHIBITORS FOR USE IN TREATMENT OF CANCER | CHONG, YONG SOO | — | §103§112 | Non-Final OA | — | Pending | Dec 10, 2024 |
| 18865873 | OPTICAL SENSOR AND ASSOCIATED METHODS | NGUYEN, SANG H | 2877 | §101§102§103 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | IVICH, FERNANDO NMN | — | §101§102§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18580742 | Treatment and/or Prevention of Digestive Disorder by a Bacterial Composition of Propionibacterium Freudenreichii and Bifidobacterium Longum | CRUM, MARY ABOU NADER | 1657 | §101§103§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18497735 | ANTI-BK VIRUS ANTIBODY MOLECULES | SZPERKA, MICHAEL EDWARD | 1641 | §102§112Other | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18491017 | NEURAL NETWORK CIRCUIT WITH DELAY LINE | HADDAD, MAJD MAHER | 4100 | §102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18039530 | Cyclic Tetrapeptides and Metal Complexes Thereof | NIEBAUER, RONALD T | 1658 | §103 | Final Rejection | — | Pending | May 31, 2023 |
| 18019382 | ANTIMICROBIAL PEPTIDOMIMETICS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §112DP | Final Rejection | 8d overdue | Pending | Feb 02, 2023 |
| 18019388 | ANTIMICROBIAL PEPTIDOMIMETICS | BEANE, RANDALL L | 1654 | DP | Final Rejection | 14d | Pending | Feb 02, 2023 |
| 17639113 | Minimal Messenger RNAs and uses thereof | MCLEOD, AFRICA MHAIRIE | 1635 | §102§112 | Final Rejection | 19d overdue | Pending | Feb 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial